» Articles » PMID: 39068625

PTGR1-mediated Immune Evasion Mechanisms in Late-stage Triple-negative Breast Cancer: Mechanisms of M2 Macrophage Infiltration and CD8 T Cell Suppression

Overview
Journal Apoptosis
Publisher Springer
Date 2024 Jul 28
PMID 39068625
Authors
Affiliations
Soon will be listed here.
Abstract

Triple-negative breast cancer (TNBC) is a heterogeneous disease characterized by metabolic dysregulation. Tumor cell immune escape plays an indispensable role in the development of TNBC tumors. Furthermore, in the abstract, we explicitly mention the techniques used and enhance the clarity and impact of our findings. "Based on bioinformatics analysis results, we utilized CRISPR/Cas9 technology to knockout the target gene and established a mouse model of breast cancer. Through experiments such as CCK8, scratch assay, and Transwell assay, we further investigated the impact of target gene knockout on the malignant behavior of tumor cells. Subsequently, we conducted immunohistochemistry and Western Blot experiments to study the expression of macrophage polarization and infiltration-related markers and evaluate the effect of the target gene on macrophage polarization. Next, through co-culture experiments, we simulated the tumor microenvironment and used immunohistochemistry staining to observe and analyze the distribution and activation status of M2 macrophages and CD8 T cells in the co-culture system. We validated in vivo experiments the molecular mechanism by which the target gene regulates immune cell impact on TNBC progression.

Citing Articles

Analysis of single-cell and spatial transcriptomics in TNBC cell-cell interactions.

Xin Y, Ma Q, Deng Q, Wang T, Wang D, Wang G Front Immunol. 2025; 16:1521388.

PMID: 40079015 PMC: 11897037. DOI: 10.3389/fimmu.2025.1521388.


NSG2: a promising prognostic marker shaping the immune landscape of breast cancer.

Li X, Gu Q, Sun P, Yang L, Zhang X, Lu B Front Immunol. 2024; 15:1487447.

PMID: 39493764 PMC: 11527618. DOI: 10.3389/fimmu.2024.1487447.

References
1.
Grasset E, Dunworth M, Sharma G, Loth M, Tandurella J, Cimino-Mathews A . Triple-negative breast cancer metastasis involves complex epithelial-mesenchymal transition dynamics and requires vimentin. Sci Transl Med. 2022; 14(656):eabn7571. PMC: 9801390. DOI: 10.1126/scitranslmed.abn7571. View

2.
Derakhshan F, Reis-Filho J . Pathogenesis of Triple-Negative Breast Cancer. Annu Rev Pathol. 2022; 17:181-204. PMC: 9231507. DOI: 10.1146/annurev-pathol-042420-093238. View

3.
Yin L, Duan J, Bian X, Yu S . Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020; 22(1):61. PMC: 7285581. DOI: 10.1186/s13058-020-01296-5. View

4.
Li M, Dong Y, Luan S, Zhao Z, Ning F . Changes of expression of estrogen and progestrone receptors, human epithelial growth factor receptor 2 and Ki-67 after neoadjuvant chemotherapy in the treatment of breast cancer. J Biol Regul Homeost Agents. 2017; 30(4):1059-1065. View

5.
Camorani S, dArgenio A, Agnello L, Nilo R, Zannetti A, Ibarra L . Optimization of Short RNA Aptamers for TNBC Cell Targeting. Int J Mol Sci. 2022; 23(7). PMC: 8998535. DOI: 10.3390/ijms23073511. View